Low Molecular Weight Heparin Prevents Adverse Pregnancy Ourcomes In Pregnant Women With Inheruted Thrombophilia:A Meta-analysis

Objective: To determine whether the use of low-molecular-weight heparin preventive anticoagulation in pregnant women with hereditary thrombophilia can improve pregnancy outcomes compared with non-use of low-molecular-weight heparin.Methods: This article is based on a randomized controlled trial(RCT)meta-analysis to verify the effect of low-molecular-weight heparin on pregnancy outcomes in pregnant women with inherited thrombophilia.All articles were retrieved from Pub Med,Embase,Cochrane Library,OVID and CNKI databases.Outcomes include live birth rate,the incidence of placental-mediated pregnancy complications such as PE,FGR,pregnancy loss,placental abruption,etc.The two completed article screening and data extraction respectively.If there is a dispute,it is decided by the two people through consultation.If the two people cannot reach a unanimous conclusion,it will be submitted to a third party for arbitration.Use Rev Man5.3 software to complete the statistical analysis.Results: Finally,11 randomized controlled trials involving a total of1054 pregnant women(569 in the LMWH group and 485 in the control group)were included in the study.Low-molecular-weight heparin has no significant effect in increasing the live birth rate [RR=1.14,95%CI(0.97,1.34),P=0.12].LMWH has no significant effect in reducing the incidence of pregnancy loss[RR=0.70,95%CI(0.29,1.65),P=0.41],pre-eclampsia[RR=0.79,95%CI(0.49,1.26),P=0.32],FGR[RR=0.72,95%CI(0.48,1.08),P=0.12] and placental abruption[RR=0.85,95%CI(0.29,2.52),P=0.77].Conclusion: LMWH cannot reduce the incidence of adverse pregnancy outcomes(pregnancy loss,PE,FGR,placental abruption)in pregnant women with inherited thrombophilia.